Immuron surges on exclusive US PROIBS launch agreement with Calmino group
Immuron announced an exclusive US distribution deal with Calmino group AB to launch PROIBS in the United States. The partnership targets a $4.16 billion US digestive health market and leverages a 1,003-person usability study showing high satisfaction (94% helpful, 91% daily-life improvement, 98% would recommend). Execution could lift revenue as PROIBS ramps alongside Travelan momentum.
View signal analysis